New and Emerging Weight Loss Drugs
The next generation of obesity medications is reaching 24-30% weight loss in trials, and the pace of development has not slowed. This hub covers every major pipeline drug with the actual trial data, honest timelines, and a consistent warning: none of these are available yet, and gray-market versions are dangerous.
9 guides in this topic · Last updated August 3, 2026
Start Here
MAIN GUIDERetatrutide: The Triple Agonist Hitting 30% Weight Loss
TRIUMPH-1 data on retatrutide, the GLP-1/GIP/glucagon triple agonist producing up to 30.3% weight loss. How it works, approval status, side effects, and why gray-market versions are dangerous.
All Emerging Drugs Guides
Amycretin: 24% Weight Loss From GLP-1 + Amylin
Novo Nordisk's GLP-1 and amylin co-agonist reached 24% weight loss in just 36 weeks, with both injectable and oral versions advancing to Phase 3. Lancet trial data, mechanism, and timeline.
MariTide: The Once-Monthly Obesity Shot
Amgen's monthly injection reached ~20% weight loss at 52 weeks with no plateau. NEJM Phase 2 data, the unusual GIP-blocking mechanism, and why 12 injections a year could change adherence.
CagriSema: The Most Powerful Weight Loss Drug Yet?
CagriSema combines cagrilintide + semaglutide for up to 25% weight loss. Clinical trial results, how it works, expected approval timeline, and how it compares to existing GLP-1s.
Survodutide for Weight Loss: New GLP-1/Glucagon Drug
Everything about survodutide, the new dual GLP-1/glucagon receptor agonist showing up to 19% weight loss in trials. How it compares to semaglutide and tirzepatide.
Mazdutide: The Dual GLP-1/Glucagon Drug Approved in China
The first glucagon/GLP-1 dual agonist approved anywhere for weight management. GLORY-1 in NEJM, 18.55% at 9 mg, and why approval in China does not make it obtainable in the US.
Petrelintide: Betting on Tolerability, Not Percentages
The Zealand/Roche amylin analog hit 10.7% at 42 weeks with placebo-like tolerability - and the stock fell anyway. Why the market judged it on the wrong axis.
Bimagrumab: The Drug That Preserves Muscle
Roughly 35% of weight lost on semaglutide is lean mass. Bimagrumab produced 10.8% weight loss that was 100% fat, with lean mass up 2.5% - and over 20% combined with semaglutide in BELIEVE.
When Will Semaglutide Go Generic?
Canada already has generic semaglutide after Novo Nordisk's patent lapsed. Country-by-country patent timeline, why the US waits until the 2030s, and how cheap generics will realistically be.
Explore Other Topics
Looking for Affordable GLP-1 Treatment?
Coreage Rx offers physician-supervised compounded semaglutide from $249/month all-inclusive - consultation, medication, shipping, and ongoing dose management in one flat price, with no insurance required.